EGLN1 and chronic kidney disease: The vast majority of investigations with pharmacologic hydroxylase inhibitors have also reported a protective effect in various models of CKD [37], overall supporting that PHD2 is a pharmaceutical relevant target for the treatment of kidney injury and disease.